ArticleScientific reports2025
Improving the performance of polymerase chain reaction for microsatellite instability testing in endometrial cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genomic innovations in cancer prevention, diagnosis, prognosis and precision therapeutics.Frontiers in genetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Between 20% and 30% of endometrial cancer (EC) cases show mismatch repair deficiency (dMMR), and its characterisation is recommended in these tumours for molecular classification, screening of Lynch syndrome, and as a predictive biomarker for immunotherapy. The aim of this study was to explore two tests developed by Promega (OncoMate MSI Dx Analysis System and long mononucleotide repeat (LMR) microsatellite instability (MSI) analysis system). DNA from 126 EC tumours had been screened for MMR status by immunohistochemistry (IHC). Overall, 67 (53.2%) dMMRs and 59 (46.8%) proficient (pMMR) were included. The same cases were additionally explored for MMR genomic status, with 55 (43.7%) cases presenting an altered genomic pattern, and 69 (54.8%) with no genomic alterations. There were 71 (56.3%) microsatellite stability (MSS) cases for OncoMate and 69 (54.8%) for LMR, and 37 (29.4%) microsatellite instability (MSI) cases for OncoMate and 44 (34.9%) for LMR. Differences between the test assignments were significant (p < 0.001), with an increased proportion of correctly classified cases for the LMR assay, taking the IHC result as the reference. The respective sensitivity and specificity of the LMR assay was 95.5% and 68.1%, versus 86.5% and 53.5% for the OncoMate assay. In conclusion, the new LMR MSI Analysis System had a higher correlation with IHC, including cases that could be misdiagnosed due to minimal shifts, as well as higher sensitivity and specificity than the OncoMate panel. The best method regarding the use of dMMR/MSI as a response biomarker for immune checkpoint inhibitors requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.